Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tedizolid Phosphate

FDA-approved product (tablet, oral), marketed as Sivextro.

Registered studies
37
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tedizolid Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antibacterials
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX11

Repurposing investigation

Tedizolid Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tedizolid Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tedizolid Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

    NCT01156077 · start 2010-06-02

    Registered record
    Registry ID
    NCT01156077
    Conditions
    Bacterial Infection
    Interventions
    TR-701 FA; TR-701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06-02
    Completion
    2011-09-24
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionTR-701 FA; TR-701 FA
    PhasePhase 1
    Registry statusCompleted

  • Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

    NCT00983255 · start 2009-09

    Registered record
    Registry ID
    NCT00983255
    Conditions
    Bacterial Infections
    Interventions
    TR-701 FA for injection, 200 mg/vial; TR-701 FA tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionTR-701 FA for injection, 200 mg/vial; TR-701 FA tablets
    PhasePhase 1
    Registry statusCompleted

  • Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

    NCT00876655 · start 2009-02

    Registered record
    Registry ID
    NCT00876655
    Conditions
    Healthy
    Interventions
    TR-701 di-sodium phosphate salt; TR-701 free acid phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTR-701 di-sodium phosphate salt; TR-701 free acid phosphate
    PhasePhase 1
    Registry statusCompleted

  • Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

    NCT00761215 · start 2008-09-17

    Registered record
    Registry ID
    NCT00761215
    Conditions
    Skin Diseases, Infectious; Skin Diseases, Bacterial
    Interventions
    TR-701 200 mg; TR-701 300 mg; TR-701 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09-17
    Completion
    2009-02-24
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious; Skin Diseases, Bacterial
    InterventionTR-701 200 mg; TR-701 300 mg; TR-701 400 mg
    PhasePhase 2
    Registry statusCompleted

  • Microdialysis and Pharmacokinetic Study of TR-701

    NCT00666601 · start 2008-04-04

    Registered record
    Registry ID
    NCT00666601
    Conditions
    Healthy
    Interventions
    TR-700 (active moiety); TR-701 (pro-drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-04-04
    Completion
    2008-08-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTR-700 (active moiety); TR-701 (pro-drug)
    PhasePhase 1
    Registry statusCompleted

  • Food Effects of Single Oral Dose of 600mg TR-701

    NCT00671359 · start 2008-03-10

    Registered record
    Registry ID
    NCT00671359
    Conditions
    Healthy
    Interventions
    TR-701 600mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03-10
    Completion
    2008-05-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTR-701 600mg
    PhasePhase 1
    Registry statusCompleted

  • Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

    NCT00671814 · start 2008-01-06

    Registered record
    Registry ID
    NCT00671814
    Conditions
    Healthy Subjects
    Interventions
    TR-701; linezolid; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01-06
    Completion
    2008-06-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionTR-701; linezolid; placebo
    PhasePhase 1
    Registry statusCompleted